Login / Signup

[Effects of sacubitril/valsartan in patients with cancer therapy-related heart failure].

M V VitsenyaAlexandra V PotekhinaS V GavryushinaN M IbragimovaO V StukalovaV P MasenkoT V SharfFail T Ageev
Published in: Terapevticheskii arkhiv (2023)
S/V therapy is associated with improvement of EF, systolic and diastolic LV function, demonstrates a favorable tolerability profile in patients with СTRHF. Lack of RT and low baseline LV EF increased the odds of LV EF improvement; lack of RT, early (≤1 year) start of treatment after discontinuation of anthracycline therapy, and age <58 years increased the odds of LV EF recovery.
Keyphrases
  • heart failure
  • left ventricular
  • cancer therapy
  • blood pressure
  • open label
  • randomized controlled trial
  • stem cells
  • clinical trial
  • acute heart failure
  • cell therapy